← Coherus Oncology, Inc. (CHRS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Coherus Oncology, Inc. (CHRS)
Biological Products, (No Diagnostic Substances) · market cap $193M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
10
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Coherus Oncology (CHRS) is a small-cap biopharma with 158 employees and a $251M market cap trading at ~$1.63/share. The company runs a mixed pipeline spanning biosimilars (etanercept/CHS-0214/CHS-1420 in Phase 3 for RA and plaque psoriasis) and oncology assets (casdozokitug and SRF388 in Phase 2 for hepatocellular carcinoma). With only ~6 months of cash runway on $115.2M in cash and revenue collapsing from $267M in 2024 to $42M in 2025, financing risk is acute.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 2 · Casdozokitugimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Casdozokitug | Phase 2 | Hepatocellular Carcinoma |
| Etanercept | Phase 3 | Rheumatoid Arthritis |
| CHS-0214 | Phase 3 | Plaque Psoriasis |
| SRF388 | Phase 2 | Hepatocellular Carcinoma |
| CHS-1420 | Phase 3 | Plaque Psoriasis |
| Toripalimab + Chemotherapy | Phase 2 | Head and Neck Cancer |
| Toripalimab-tpzi | Phase 2 | Squamous Cell Carcinoma |
| STC-15 monotherapy | Phase 2 | Solid Tumor |
| Toripalimab | Phase 2 | Sinonasal Cancer |
| Nadunolimab | Phase 2 | Metastatic Microsatellite Stable Colorectal Carcinoma |
Price & technical context
3-month
-20.0%
6-month
-33.3%
12-month
-29.3%
52-wk range
$1.10–$2.51
vs 50-day MA
-12.5%
vs 200-day MA
-26.3%
Realized vol
79.5%
Max drawdown
-57.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CHRS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.